See more : Polytex India Limited (POLYTEX.BO) Income Statement Analysis – Financial Results
Complete financial analysis of West Pharmaceutical Services, Inc. (WST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of West Pharmaceutical Services, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- Aeternal Mentis, S.A. (AMEN.MC) Income Statement Analysis – Financial Results
- Zuken Inc. (6947.T) Income Statement Analysis – Financial Results
- Matsumoto Yushi-Seiyaku Co.,Ltd. (4365.T) Income Statement Analysis – Financial Results
- Magnum Berhad (3859.KL) Income Statement Analysis – Financial Results
- Vertical International Holdings Limited (8375.HK) Income Statement Analysis – Financial Results
West Pharmaceutical Services, Inc. (WST)
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.95B | 2.89B | 2.83B | 2.15B | 1.84B | 1.72B | 1.60B | 1.51B | 1.40B | 1.42B | 1.37B | 1.27B | 1.19B | 1.10B | 1.06B | 1.05B | 1.02B | 913.30M | 699.70M | 541.60M | 490.70M | 419.70M | 396.90M | 430.10M | 469.10M | 449.70M | 452.50M | 458.80M | 412.90M | 365.10M | 348.70M | 338.20M | 329.60M | 323.20M | 308.70M | 288.20M | 253.30M | 235.60M | 190.10M |
| Cost of Revenue | 1.82B | 1.75B | 1.66B | 1.38B | 1.23B | 1.17B | 1.09B | 1.01B | 944.00M | 973.60M | 933.70M | 878.70M | 853.00M | 786.60M | 752.10M | 748.50M | 728.30M | 651.50M | 507.10M | 385.70M | 334.90M | 302.10M | 280.80M | 289.70M | 289.10M | 282.20M | 288.50M | 302.00M | 265.10M | 225.90M | 222.10M | 217.80M | 221.40M | 221.50M | 206.70M | 197.40M | 174.40M | 160.20M | 128.00M |
| Gross Profit | 1.13B | 1.14B | 1.18B | 767.80M | 605.70M | 545.40M | 512.60M | 501.10M | 455.80M | 447.80M | 434.70M | 387.70M | 339.30M | 318.10M | 303.60M | 302.60M | 291.80M | 261.80M | 192.60M | 155.90M | 155.80M | 117.60M | 116.10M | 140.40M | 180.00M | 167.50M | 164.00M | 156.80M | 147.80M | 139.20M | 126.60M | 120.40M | 108.20M | 101.70M | 102.00M | 90.80M | 78.90M | 75.40M | 62.10M |
| Gross Profit Ratio | 38.28% | 39.36% | 41.52% | 35.76% | 32.92% | 31.76% | 32.06% | 33.21% | 32.56% | 31.50% | 31.77% | 30.61% | 28.46% | 28.80% | 28.76% | 28.79% | 28.61% | 28.67% | 27.53% | 28.79% | 31.75% | 28.02% | 29.25% | 32.64% | 38.37% | 37.25% | 36.24% | 34.18% | 35.80% | 38.13% | 36.31% | 35.60% | 32.83% | 31.47% | 33.04% | 31.51% | 31.15% | 32.00% | 32.67% |
| Research & Development | 68.40M | 58.50M | 52.80M | 46.90M | 38.90M | 40.30M | 39.10M | 36.80M | 34.10M | 37.30M | 37.90M | 33.20M | 29.10M | 23.90M | 19.90M | 18.70M | 16.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 262.90M | 242.60M | 239.80M | 233.00M | 228.70M | 234.90M | 218.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 353.40M | 316.90M | 362.80M | 302.00M | 272.70M | 262.90M | 242.60M | 239.80M | 233.00M | 228.70M | 234.90M | 218.10M | 191.10M | 187.70M | 177.70M | 159.30M | 152.50M | 155.90M | 120.30M | 105.20M | 111.00M | 82.60M | 73.40M | 67.70M | 77.90M | 70.50M | 70.20M | 72.80M | 69.90M | 69.00M | 63.50M | 57.10M | 85.00M | 57.80M | 45.60M | 41.50M | 32.20M | 29.90M | 26.60M |
| Other Expenses | 31.50M | 26.80M | 7.90M | 12.00M | 2.40M | 4.80M | -2.00M | -27.70M | -60.10M | 200.00K | 500.00K | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 454.00M | 402.20M | 423.50M | 360.90M | 311.60M | 303.20M | 281.70M | 276.60M | 267.10M | 266.00M | 272.80M | 251.30M | 221.70M | 213.30M | 197.60M | 191.90M | 168.60M | 160.80M | 121.70M | 106.70M | 94.30M | 81.00M | 71.90M | 104.70M | 113.60M | 102.80M | 102.10M | 103.50M | 99.50M | 92.10M | 85.50M | 80.70M | 109.50M | 80.50M | 65.90M | 60.40M | 49.00M | 44.60M | 38.60M |
| Cost & Expenses | 2.27B | 2.15B | 2.08B | 1.74B | 1.55B | 1.48B | 1.37B | 1.28B | 1.21B | 1.24B | 1.21B | 1.13B | 1.07B | 999.90M | 949.70M | 940.40M | 896.90M | 812.30M | 628.80M | 492.40M | 429.20M | 383.10M | 352.70M | 394.40M | 402.70M | 385.00M | 390.60M | 405.50M | 364.60M | 318.00M | 307.60M | 298.50M | 330.90M | 302.00M | 272.60M | 257.80M | 223.40M | 204.80M | 166.60M |
| Interest Income | 28.00M | 5.10M | 1.00M | 1.40M | 3.80M | 2.10M | 1.30M | 1.10M | 1.60M | 3.50M | 1.90M | 1.80M | 1.30M | 600.00K | 800.00K | 1.40M | 6.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.00M | 7.90M | 7.20M | 6.80M | 4.70M | 6.30M | 6.50M | 7.00M | 12.50M | 13.00M | 15.10M | 14.90M | 18.20M | 16.80M | 14.40M | 16.00M | 14.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 137.30M | 120.60M | 122.30M | 109.10M | 103.40M | 104.40M | 96.70M | 90.70M | 89.90M | 90.00M | 85.20M | 76.90M | 75.70M | 73.20M | 68.10M | 60.60M | 56.60M | 52.70M | 47.40M | 33.20M | 33.00M | 33.00M | 32.00M | 37.00M | 35.70M | 32.30M | 31.90M | 30.70M | 29.60M | 23.10M | 22.00M | 23.60M | 24.50M | 22.70M | 20.30M | 18.90M | 16.80M | 14.70M | 12.00M |
| EBITDA | 844.10M | 887.90M | 895.20M | 531.70M | 399.40M | 355.30M | 335.90M | 319.60M | 220.00M | 273.30M | 249.00M | 200.00M | 183.40M | 161.30M | 166.40M | 186.10M | 157.50M | 149.90M | 122.90M | 94.50M | 84.80M | 82.80M | 74.70M | 75.90M | 102.10M | 97.00M | 93.80M | 84.00M | 77.90M | 70.20M | 63.10M | 63.30M | 23.20M | 43.90M | 56.40M | 49.30M | 46.70M | 45.50M | 35.50M |
| EBITDA Ratio | 28.62% | 29.60% | 31.02% | 24.09% | 21.73% | 14.38% | 14.31% | 13.04% | 9.19% | 12.80% | 11.87% | 11.20% | 10.53% | 10.76% | 9.95% | 10.65% | 20.40% | 18.01% | 19.39% | 15.68% | 17.28% | 18.56% | 19.55% | 21.39% | 21.49% | 28.13% | 20.38% | 22.47% | 18.29% | 19.56% | 17.95% | 18.72% | 6.71% | 14.91% | 16.94% | 16.20% | 19.31% | 18.34% | 16.99% |
| Operating Income | 676.00M | 734.00M | 752.30M | 406.90M | 296.60M | 240.30M | 228.90M | 196.80M | 128.60M | 182.00M | 162.40M | 135.10M | 109.60M | 90.70M | 97.50M | 124.10M | 94.90M | 101.00M | 72.20M | 48.20M | 54.50M | 26.70M | 41.30M | 35.70M | 66.40M | 64.70M | 61.90M | 53.30M | 48.30M | 47.10M | 41.10M | 39.70M | -1.30M | 21.20M | 36.10M | 30.40M | 29.90M | 30.80M | 23.50M |
| Operating Income Ratio | 22.92% | 25.43% | 26.57% | 18.95% | 16.12% | 13.99% | 14.31% | 13.04% | 9.19% | 12.80% | 11.87% | 10.67% | 9.19% | 8.21% | 9.24% | 11.81% | 9.30% | 11.06% | 10.32% | 8.90% | 11.11% | 6.36% | 10.41% | 8.30% | 14.15% | 14.39% | 13.68% | 11.62% | 11.70% | 12.90% | 11.79% | 11.74% | -0.39% | 6.56% | 11.69% | 10.55% | 11.80% | 13.07% | 12.36% |
| Total Other Income/Expenses | 22.00M | -54.10M | -3.40M | -5.60M | -4.80M | 400.00K | -3.40M | -5.40M | -12.50M | -13.00M | -15.30M | -26.50M | -23.20M | -31.50M | -14.40M | -15.10M | -8.50M | -16.50M | -12.00M | -8.20M | -7.50M | -9.50M | -13.40M | -11.10M | -9.30M | -36.80M | -4.20M | -26.10M | -5.70M | -6.40M | -4.30M | -5.70M | -2.50M | -10.50M | -2.20M | -2.90M | -6.70M | -600.00K | 1.90M |
| Income Before Tax | 698.00M | 679.90M | 748.90M | 401.30M | 291.80M | 240.70M | 222.40M | 189.80M | 116.10M | 169.00M | 147.10M | 108.60M | 92.70M | 74.50M | 83.10M | 109.50M | 86.40M | 84.50M | 45.20M | 41.20M | 47.00M | 17.20M | 27.80M | 3.10M | 57.10M | 27.90M | 57.70M | 27.20M | 42.60M | 40.70M | 36.80M | 34.00M | -3.80M | 10.70M | 33.90M | 27.50M | 23.20M | 30.20M | 25.40M |
| Income Before Tax Ratio | 23.66% | 23.55% | 26.45% | 18.69% | 15.86% | 14.02% | 13.91% | 12.58% | 8.29% | 11.89% | 10.75% | 8.58% | 7.77% | 6.74% | 7.87% | 10.42% | 8.47% | 9.25% | 6.46% | 7.61% | 9.58% | 4.10% | 7.00% | 0.72% | 12.17% | 6.20% | 12.75% | 5.93% | 10.32% | 11.15% | 10.55% | 10.05% | -1.15% | 3.31% | 10.98% | 9.54% | 9.16% | 12.82% | 13.36% |
| Income Tax Expense | 122.30M | 114.70M | 107.20M | 72.50M | 59.00M | 41.40M | 80.90M | 54.40M | 26.30M | 47.20M | 40.20M | 32.70M | 23.50M | 13.60M | 13.50M | 23.70M | 17.20M | 24.60M | -400.00K | 11.10M | 16.70M | 4.10M | 8.60M | 1.50M | 18.40M | 21.20M | 13.30M | 10.80M | 13.90M | 13.40M | 14.30M | 14.30M | 4.70M | 6.40M | 13.20M | 10.10M | 9.50M | 13.20M | 10.40M |
| Net Income | 593.40M | 585.90M | 661.80M | 346.20M | 241.70M | 206.90M | 150.70M | 143.60M | 95.60M | 127.10M | 112.30M | 80.70M | 75.50M | 65.30M | 72.60M | 86.00M | 70.70M | 67.10M | 45.60M | 19.40M | 31.90M | 18.40M | -5.20M | 1.60M | 38.70M | 6.70M | 44.40M | 16.40M | 28.70M | 27.30M | 23.50M | 19.70M | -8.50M | 4.30M | 20.70M | 17.40M | 13.70M | 17.00M | 15.00M |
| Net Income Ratio | 20.12% | 20.30% | 23.37% | 16.13% | 13.14% | 12.05% | 9.42% | 9.52% | 6.83% | 8.94% | 8.21% | 6.37% | 6.33% | 5.91% | 6.88% | 8.18% | 6.93% | 7.35% | 6.52% | 3.58% | 6.50% | 4.38% | -1.31% | 0.37% | 8.25% | 1.49% | 9.81% | 3.57% | 6.95% | 7.48% | 6.74% | 5.82% | -2.58% | 1.33% | 6.71% | 6.04% | 5.41% | 7.22% | 7.89% |
| EPS | 7.99 | 7.88 | 8.90 | 4.68 | 3.27 | 2.80 | 2.04 | 1.96 | 1.33 | 1.79 | 1.61 | 1.19 | 1.12 | 0.98 | 1.11 | 1.33 | 1.08 | 1.05 | 0.75 | 0.57 | 0.75 | 0.33 | -0.09 | 0.03 | 0.65 | 0.10 | 0.67 | 0.25 | 0.43 | 0.43 | 0.37 | 0.32 | -0.14 | 0.07 | 0.32 | 0.27 | 0.21 | 0.27 | 0.24 |
| EPS Diluted | 7.88 | 7.73 | 8.67 | 4.57 | 3.21 | 2.74 | 1.99 | 1.91 | 1.30 | 1.75 | 1.57 | 1.15 | 1.08 | 0.95 | 1.06 | 1.25 | 1.02 | 1.00 | 0.71 | 0.56 | 0.75 | 0.33 | -0.09 | 0.03 | 0.64 | 0.10 | 0.67 | 0.25 | 0.43 | 0.43 | 0.37 | 0.31 | -0.14 | 0.07 | 0.32 | 0.27 | 0.21 | 0.27 | 0.24 |
| Weighted Avg Shares Out | 74.30M | 74.40M | 74.40M | 73.90M | 74.00M | 73.90M | 73.90M | 73.30M | 72.00M | 70.90M | 69.60M | 68.00M | 67.40M | 66.60M | 65.60M | 64.80M | 65.40M | 64.40M | 62.20M | 60.00M | 58.00M | 57.80M | 57.34M | 57.63M | 59.66M | 65.74M | 65.90M | 65.67M | 66.23M | 64.22M | 63.51M | 62.54M | 61.82M | 63.70M | 64.69M | 65.05M | 64.47M | 64.15M | 63.16M |
| Weighted Avg Shares Out (Dil) | 75.30M | 75.80M | 76.30M | 75.80M | 75.40M | 75.40M | 75.80M | 75.00M | 73.80M | 72.80M | 71.40M | 71.80M | 74.00M | 73.40M | 72.60M | 72.20M | 72.40M | 67.20M | 65.00M | 61.60M | 58.20M | 57.80M | 57.39M | 57.64M | 60.19M | 66.02M | 66.29M | 65.67M | 66.23M | 64.22M | 63.95M | 63.04M | 61.82M | 63.70M | 65.20M | 65.05M | 64.47M | 64.15M | 63.16M |
4 Stocks to Buy Amid Dental Supplies Industry Challenges
Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.
West Introduces Daikyo Crystal Zenith® (CZ) Ready-to-Use Nested Vials in Tub at the International Society for Cell and Gene Therapy
CZ's Nested Vials are designed to meet the exterior dimensions of glass standard ISO 8362-1 and offer broad compatibility with various aseptic fill-finish equipment available in the market. EXTON, Pa.
10 Dividend Growth Stocks: May 2024
In this series, I rank a selection of dividend growth stocks in Dividend Radar and present the ten top-ranked stocks for consideration. To rank stocks, I do a quality assessment and sort stocks by quality scores, breaking ties with additional...
West to Participate in Upcoming Investor Conference
EXTON, Pa. , May 28, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the William Blair 44th Annual Growth Stock Conference in...
Q2 2024 EPS Estimates for West Pharmaceutical Services, Inc. (NYSE:WST) Cut by Analyst
West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) – Stock analysts at Zacks Research dropped their Q2 2024 earnings estimates for West Pharmaceutical Services in a research note issued on Thursday, May 16th. Zacks Research analyst I. Bandyopadhyay now expects...
West to Participate in Upcoming Investor Conference
EXTON, Pa. , April 30, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Bank of America Securities Healthcare Conference in Las...
West Pharmaceutical Services, Inc. (WST) Q1 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q1 2024 Earnings Conference Call April 25, 2024 9:00 AM ET Company Participants Quintin Lai - Vice President, Strategy and Investor Relations Eric Green - President and Chief Executive Officer Bernard Birkett - Senior...
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
West Pharmaceutical Services (WST) Tops Q1 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.56 per share, beating the Zacks Consensus Estimate of $1.29 per share. This compares to earnings of $1.98 per share a year ago.
West Pharma posts beat-and-raise quarter aided by strong demand for injectables
West Pharmaceutical Services on Thursday beat quarterly profit estimates and raised its annual profit forecast, banking on rising demand for cartridges and syringes used to manufacture injectable therapies.
Source: https://incomestatements.info
Category: Stock Reports
What were West Pharmaceutical’s net sales in Q3 2024?
(NYSE: WST) today announced its financial results for the third-quarter 2024 and declared a fourth-quarter 2024 dividend. Net sales of $746.9 million declined 0.1%; organic net sales decline was 0.5%. Reported-diluted EPS of $1.85, compared to $2.14 in the same period last year.